Swiss Centre for Regenerative Medicine, University of Zurich, Switzerland.
Swiss Med Wkly. 2012 Jul 16;142:w13622. doi: 10.4414/smw.2012.13622. eCollection 2012.
Heart valve tissue engineering holds the potential to overcome limitations of currently used heart valve prostheses. It involves the isolation and expansion of autologous patient cells, the subsequent seeding of these cells onto an appropriate scaffold material, the in vitro incubation and the in vivo implantation of the derived tissue-engineered construct into the patient from whom the cells were taken. While vascular-derived cells require harvest of intact donor tissue and show limited expansion capacities, the use of stem or progenitor cells may overcome these limitations and expand the versatility of the concept of heart valve tissue engineering. Possible sources include cells isolated from blood, bone marrow, adipose tissue, amniotic fluid, chorionic villi, umbilical cord and induced pluripotent stem cells. Here we review different stem cell sources with particular regard to cellular phenotypes and their suitability for application in heart valve tissue engineering.
心脏瓣膜组织工程有潜力克服目前使用的心脏瓣膜假体的局限性。它涉及自体患者细胞的分离和扩增，随后将这些细胞接种到合适的支架材料上，在体外孵育和将衍生的组织工程构建体植入取自细胞的患者体内。虽然血管来源的细胞需要完整供体组织的采集，并且显示出有限的扩增能力，但使用干细胞或祖细胞可能克服这些限制，并扩大心脏瓣膜组织工程概念的多功能性。可能的来源包括从血液、骨髓、脂肪组织、羊水、绒毛膜绒毛、脐带和诱导多能干细胞中分离出的细胞。在这里，我们特别关注细胞表型及其在心脏瓣膜组织工程中的适用性，综述了不同的干细胞来源。
